Eli – Page 3 – Talk Bio

Eli Lilly Acquires Scorpion Therapeutics in $2.5 Billion Deal to Boost Breast Cancer Treatment Options

5 months ago talkbio0Tagged Eli, Eli Lilly, Inhibitor, Malignant neoplasm of breast, Oncology Pipeline, PI3Kδ, Scorpions, STX-478

Eli Lilly, Scorpion Therapeutics, breast cancer, PI3Kα inhibitor, STX-478, oncology pipeline, targeted therapy

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

5 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.

Eli Lilly and Alchemab Therapeutics Collaborate on Novel ALS Therapies

5 months ago talkbio0Tagged Alchemab, Amyotrophic Lateral Sclerosis, Drug Development, Eli, Eli Lilly, Neurodegenerative Disorders, Therapeutic Antibodies

Eli Lilly, Alchemab Therapeutics, ALS, Therapeutic Antibodies, Neurodegenerative Disease, Drug Development

Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies

5 months ago talkbio0Tagged blockbuster drugs, Clarivate, Drug Industry, Eli, Eli Lilly, gene therapy, Neoplasms, Nordisk, Obesity

Clarivate, Drugs to Watch 2025, Novo Nordisk, Eli Lilly, Obesity treatments, Gene therapy, Oncology, Blockbuster drugs, Pharmaceutical industry

Eli Lilly Seeks to Intervene in FDA Lawsuit Over Compounded Tirzepatide to Safeguard Interests

5 months ago talkbio0Tagged Drug Industry, Eli, Eli Lilly, lawsuit, regulatory issues, United States Food and Drug Administration, Weight-Loss Agents

Eli Lilly, FDA lawsuit, compounded tirzepatide, weight loss drugs, pharmaceutical industry, regulatory issues

Eli Lilly Intervenes in Lawsuit to Block Compounded Versions of Tirzepatide Following FDA’s Shortage Resolution

5 months ago talkbio0Tagged Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Pharmacy facility, shortage, United States Food and Drug Administration, Zepbound

Eli Lilly, tirzepatide, GLP-1 shortage, FDA, compounding pharmacies, lawsuit, Mounjaro, Zepbound

FDA Reaffirms End of Tirzepatide Shortage, Impacting Compounders

6 months ago talkbio0Tagged Compounders, Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, United States Food and Drug Administration, Zepbound

FDA, tirzepatide, GLP-1, drug shortage, compounders, Eli Lilly, Mounjaro, Zepbound

Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment

6 months ago talkbio0Tagged Affordable medication, CALR gene, Eli, Eli Lilly, Obesity, Pharmaceutical Services, Self-pay, single-dose, Telemedicine, Zepbound

Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy

Eli Lilly Announces $15 Billion Share Buyback Plan and 15% Dividend Increase

6 months ago talkbio0Tagged dividend, Drug Industry, Eli, Eli Lilly, Increase, Market, Share Buyback

Eli Lilly, Share Buyback, Dividend Increase, Pharmaceutical Industry, Stock Market

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

6 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety